SCHEMBL129884

SCHEMBL129884

O[C]1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285689 0.84
SCHEMBL3138187 0.80 TSHR (0.39)
SCHEMBL3142403 0.80 TSHR (0.39)
SCHEMBL3144028 0.80 TSHR (0.39)
SCHEMBL1379941 0.80
SCHEMBL3146489 0.80 TSHR (0.39)
SCHEMBL127435 0.76
SCHEMBL2007584 0.71
SCHEMBL16569589 0.60
SCHEMBL689737 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1692 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4385980-A1 INDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2024-06-19 EP claimed
EP-4376819-A1 USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS Boehringer Ingelheim Vetmedica GmbH (DE) 2024-06-05 EP claimed
EP-4376829-A1 USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES Boehringer Ingelheim Vetmedica GmbH (DE) 2024-06-05 EP claimed
EP-4378936-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER Hinova Pharmaceuticals Inc. (CN) 2024-06-05 EP claimed
EP-4376830-A1 USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS Boehringer Ingelheim Vetmedica GmbH (DE) 2024-06-05 EP claimed
WO-2024088922-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. HOFFMANN-LA ROCHE AG (CH) 2024-05-02 WO claimed
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 CN claimed
CN-117715640-A Use of SGLT-2 inhibitors for preventing and/or treating heart diseases in non-human mammals excluding felines, particularly canines 勃林格殷格翰动物保健有限公司 2024-03-15 CN claimed
CN-117715639-A Use of SGLT-2 inhibitors for the prevention and/or treatment of kidney disease in non-human mammals 勃林格殷格翰动物保健有限公司 2024-03-15 CN claimed
EP-3658539-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2024-02-21 EP claimed
US-20030187009-A1 Analgesics, diarrhea, anticonvulsants, antitussive agents or drug abuse therapy RENSSELAER POLYTECHNIC INSTITUTE 2003-10-02 US claimed
EP-1335723-A1 USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING OSTEOPOROSIS Bayer Aktiengesellschaft (DE) 2003-08-20 EP claimed
WO-2003015770-A1 NOVEL COMBINATION BAYER HEALTHCARE AG (DE) 2003-02-27 WO claimed
WO-2002036573-A2 8- SUBSTITUTED-2, 6-METHANO-3-BENZAZOCINES AND 3-SUBSTITUTED MORPHINANES AS OPIOID RECEPTOR BINDING AGENTS RENSSELAER POLYTECHNIC INSTITUTE (US) 2002-05-10 WO claimed
WO-2002036120-A1 USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING OSTEOPOROSIS BAYER AKTIENGESELLSCHAFT (DE) 2002-05-10 WO claimed
WO-2001047494-A1 METHOD FOR CO-GRINDING SUBSTANCES AND LACTOSE BY MEANS OF JET MILS BAYER AKTIENGESELLSCHAFT (DE) 2001-07-05 WO claimed
EP-1102767-A1 SUBSTITUTED PYRAZOLE DERIVATIVES Bayer Aktiengesellschaft (DE) 2001-05-30 EP claimed
WO-2000006568-A1 SUBSTITUTED PYRAZOLE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2000-02-10 WO claimed
US-4001218-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DT) 1977-01-04 US claimed
US-3931153-A BACTERICIDE BAYER AKTIENGESELLSCHAFT (DT) 1976-01-06 US claimed